India, Aug. 29 -- The Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) facility at Wadki in Pune, citing violations related to the packaging, recall and storage of medicines, including Reactin Plus tablets, a Schedule H prescription drug.

The licences were cancelled with effect from August 27, the FDA said in a statement issued on Friday, following an inspection of its main warehouse at Wadki.

"Strict compliance with legal provisions is essential, particularly in the advertising, sale, storage and distribution of Schedule H prescription medicines. Any violation by any part of the drug manufacturing or distribution system will invite stric...